CRISPincette MultiCancer: Finding a Needle in a Haystack

Seoul, South Korea

GeneCker is a biotechnology company specializing in ultra-precision CRISPR technology and the MUTE-Seq® platform—an ultrasensitive liquid-biopsy NGS solution. From research and development to kit manufacturing, we provide an end-to-end service for advanced cancer genomics. Our flagship CRISPincette MultiCancer kit incorporates both our patented MUTE-Seq® and CRISPR Cas9 technologies to enrich variant-containing DNA fragments for accurate multi-cancer risk assessment. With operations in Korea, China, and other global markets, GeneCker delivers solutions for Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring at ~20× higher analytical precision and one-tenth the per-sample cost compared to conventional UMI-based NGS.